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Despite looking superficially unremarkable, the clinically
uninvolved skin of patients with chronic plaque psoriasis has
been shown to have a number of distinctions when com-
pared with the skin of healthy control volunteers. The Koeb-
ner response,1 first described in 1876, as well as other
studies on the abnormesverhalten or the abnormal behaviour of
uninvolved skin,2 began to establish these differences but
their underlying mechanisms could only be the subject of
conjecture. Reports from the 1980s, making use of newly
available monoclonal antibodies, found increased numbers of
CD4+ and CD8+ T cells in the uninvolved skin of patients
with guttate psoriasis,3 which gave an immunological basis
to these discussions. Over the last 15 years, transcriptomic
studies using microarrays, and later RNA-seq, have revealed a
striking pattern of differential gene expression between
lesional psoriasis skin and clinically uninvolved skin.4–7 How-
ever, fewer studies have focused on the differences between
clinically uninvolved skin and the normal skin of unaffected
control subjects. The first direct treatment of such6 revealed
that while clinically uninvolved skin and healthy skin tran-
scriptomes appeared to cluster together, setting a threshold
to count all genes at least 13-fold altered in expression
(with false discovery rate corrected P-value < 005) identi-
fied 58 genes upregulated and 121 genes downregulated in
uninvolved psoriatic skin. These 179 differentially expressed
genes encoded proteins involved in epidermal differentia-
tion, antimicrobial defences, lipid metabolism and regulation
of cutaneous vasculature. These results identified a ‘prepsori-
atic’ gene expression signature within uninvolved skin and
pointed to decreased lipid biosynthesis and increased innate
immunity in clinically uninvolved psoriatic skin. In this
issue of the BJD, Chiricozzi and colleagues show that unin-
volved psoriasis skin, distant from lesions, displays the
molecular signature of interleukin (IL)-17 activity, in that
there is elevated expression of genes downstream of IL-17,
suggesting that the increased levels of IL-17 circulating in
the blood of patients with psoriasis impacts nonlesional
skin. Expanding on this, the authors use gene set enrich-
ment analysis (GSEA),9 a powerful statistical tool to identify
significantly enriched or underrepresented groups of genes
within large datasets (e.g. cDNA microarrays, RNA-seq or
proteomics datasets). In this instance, the authors show that
within the transcriptome of nonlesional psoriasis skin hides
the gene set upregulated in psoriasis lesions, as well as ker-
atinocyte gene sets induced by the action of IL-17A,
IL17A+TNF (tumour necrosis factor)-a and IL-17A+IL-22,
key cytokines in the pathogenesis of psoriasis. Interestingly,
GSEA also detected the presence of T-helper (Th)1, Th17,
Th22 and Th2 T-cell signatures in the nonlesional skin. This
was likely a result of circulating cytokines acting on the
uninvolved skin, but also could suggest the presence of
resting resident memory T cells, particularly in resolved
lesions;10 alternatively this ‘residual disease genomic profile’
could be the ‘molecular scar’ remaining in formerly lesional
skin.11 Given these most recent observations and the devel-
opment of multiomics studies harnessing transcriptomics,
lipidomics, proteomics, epigenetics and genetics, we are
approaching an era where we will be able to provide a full
mechanistic rationale for the ‘abnormal behaviour’ of clini-
cally uninvolved skin.
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The treatment of patients with metastatic melanoma has been
a major therapeutic challenge for decades, and only recently
has significant progress in the treatment of the disease been
made. In the last 4–5 years, new targeted therapies such as
BRAF and mitogen-activated protein kinase (MEK) inhibitors
have been introduced into the armamentarium for patients
whose melanoma harbours the V600 BRAF mutation. In addi-
tion, we have seen a significant expansion in the field of
immunotherapy: ipilimumab, cytotoxic T-lymphocyte-asso-
ciated protein 4 blocking antibody, pembrolizumab and nivo-
lumab, and programmed cell death protein 1 blocking
antibodies have joined high-dose interleukin 2 as therapeutic
options.
Ipilimumab was approved based on the results of a phase
III trial in which patients were randomized to ipilimumab
alone, ipilimumab in combination with gp100 vaccine and
gp100 vaccine alone.1 Despite a low response rate of 11%,
treatment with ipilimumab led to a near 4-month improve-
ment in overall survival (101 months in the ipilimumab arm
and 64 months in the gp100 arm). The recently published
data on the follow-up of 1861 patients treated with ipili-
mumab show a plateau, starting at 3 years, in the survival
curve at 21%.2 This long-term benefit of the therapy made
ipilimumab an attractive therapeutic option; however, as only
a minority of patients benefit, a significant effort has been put
in the search of predictive and prognostic biomarkers.
The article by Zaragoza et al. in this issue of the BJD
describes the analysis of the outcome of 58 consecutive
patients treated with ipilimumab in a single institution.3
The authors show that patients with a neutrophil-to-lym-
phocyte ratio (NLR) > 4 had a significantly shortened sur-
vival. Caution must be exercised if attempting to use these
results in clinical practice. Did the authors study a prognos-
tic or a predictive biomarker? Prognostic biomarkers corre-
late with the natural progression or aggressiveness of a
disease and are used to estimate median survival. Predictive
biomarkers are used to estimate probability for a response
to a given treatment, and therefore they are especially valu-
able when assessed before the treatment is initiated.4 When
participants are not randomly assigned to an intervention it
is nearly impossible to assess the impact of this intervention
on the outcome. In this research, the authors measured a
biomarker (NLR) before the intervention (treatment with
ipilimumab), but they did not randomize patients to a
‘treatment’ or ‘no treatment’ group. Therefore, the results
tell us nothing about how predictive NLR is for response to
the treatment, but they do tell us that NLR has a prognostic
value, that is, the worse prognosis when NLR is elevated
will not be overcome with the use of ipilimumab. I
strongly discourage clinicians to use the NLR when they
make a decision on the choice of the therapy, but I
encourage them to use it as a part of the discussion with
patients on their prognosis.
To date, no true predictive biomarkers for the response to
therapy with ipilimumab have been identified. The findings
supporting the presence of germline genetic factors associ-
ated with response to ipilimumab therapy are especially
intriguing.5 In order to confirm the validity of this discovery
a larger number of samples would have to be analysed and
the findings would require validation in an independent
cohort.
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